Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
B. Kaplan-M, B. Storyk.
The cyclooxygenase-2 inhibitors: safety and effectiveness.
Ann Pharmacother, 33 (1999), pp. 979-988
[2.]
Editorial. COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
MJA, 171 (1999), pp. 175-176
[4.]
Celecoxib approved as NSAID with some concessions on class warning.
Am J Health-Syst Pharm, 56 (1999), pp. 403
[5.]
Anónimo.
Rofecoxib forosteoarthritis andpain.
Med Lett, 41 (1999), pp. 59-61
[6.]
M.J. Langman, et al.
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA, 282 (1999), pp. 1929-1933
[7.]
Cox-1-sparing NSAIDs -is the enthusiasm justified?.
JAMA, (1999), pp. 282
[8.]
Drugdex
[9.]
Pharmaprojects
[García, 1994]
LA. García.
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs, 343 (1994), pp. 769-772
[Hochberg, 1995]
M.C. Hochberg.
Guidelines for the medical management of osteoarthritis.
Arth & Rheum, 38 (1995), pp. 1541-1546
[Lanas, 1998]
A. Lanas.
Estrategias en la prevención de la gastropatía por AINE.
Gastroenterol Hepatol, 21 (1998), pp. 48-54
[Lanza, 1998]
F.L. Lanza.
A guideline for the treatment and prevention of NSAID-induced ulcers.
AJG, 93 (1998), pp. 2037-2046
[MacDonald, 1997]
T.M. MacDonald.
Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study.
BMJ, 315 (1997), pp. 1333-1337
[Wolfe, 1999]
M.M. Wolfe.
Gastrointestinal toxicity of nonsteroidal antiinflamatory drugs.
N Eng J Med, 340 (1999), pp. 1888-1899
Este protocolo es el resultado de un trabajo conjunto de la semFYC (Sociedad Española de Medicina de Familia y Comunitaria), la SER (Sociedad Española de Reumatologia) y el Ministerio de Sanidad, para el uso racional de rofecoxib.
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
